Stock Scorecard
Stock Summary for Avadel Pharmaceuticals plc (AVDL) - $21.55 as of 2/2/2026 10:05:35 AM EST
Total Score
5 out of 30
Safety Score
32 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for AVDL
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for AVDL
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for AVDL
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for AVDL
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for AVDL (32 out of 100)
| Stock Price Rating (Max of 10) | 7 |
| Historical Stock Price Rating (Max of 10) | 4 |
| Stock Price Trend (Max of 10) | 10 |
| Book Value (Max of 10) | 2 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 0 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 1 |
| Trading Volume (Max of 10) | 8 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Financial Details for AVDL
Company Overview |
|
|---|---|
| Ticker | AVDL |
| Company Name | Avadel Pharmaceuticals plc |
| Country | USA |
| Description | Avadel Pharmaceuticals PLC is a biopharmaceutical company headquartered in Dublin, dedicated to developing innovative therapies targeting rare and complex medical conditions, with a strong emphasis on sleep medicine and endocrine disorders. The company boasts a promising product pipeline, leveraging its specialized expertise in drug formulation and delivery to address significant unmet medical needs. With a strategic focus on forming partnerships to enhance its market presence and accelerate development timelines, Avadel is well-positioned for substantial growth while striving to improve patient outcomes in vital therapeutic areas. |
| Sector Name | HEALTHCARE |
| Industry Name | DRUG MANUFACTURERS - SPECIALTY & GENERIC |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 3/2/2026 |
Stock Price History |
|
| Last Day Price | 21.55 |
| Price 4 Years Ago | 7.16 |
| Last Day Price Updated | 2/2/2026 10:05:35 AM EST |
| Last Day Volume | 797,380 |
| Average Daily Volume | 1,394,508 |
| 52-Week High | 23.57 |
| 52-Week Low | 6.38 |
| Last Price to 52 Week Low | 237.77% |
Valuation Measures |
|
| Trailing PE | 0.00 |
| Industry PE | 111.70 |
| Sector PE | 188.49 |
| 5-Year Average PE | 22.67 |
| Free Cash Flow Ratio | 26.60 |
| Industry Free Cash Flow Ratio | 9.43 |
| Sector Free Cash Flow Ratio | 30.14 |
| Current Ratio Most Recent Quarter | 2.76 |
| Total Cash Per Share | 0.81 |
| Book Value Per Share Most Recent Quarter | 1.01 |
| Price to Book Ratio | 21.55 |
| Industry Price to Book Ratio | 15.81 |
| Sector Price to Book Ratio | 57.14 |
| Price to Sales Ratio Twelve Trailing Months | 8.52 |
| Industry Price to Sales Ratio Twelve Trailing Months | 2.96 |
| Sector Price to Sales Ratio Twelve Trailing Months | 20.56 |
| Analyst Buy Ratings | 0 |
| Analyst Strong Buy Ratings | 0 |
Share Statistics |
|
| Total Shares Outstanding | 98,151,000 |
| Market Capitalization | 2,115,154,050 |
| Institutional Ownership | 95.92% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.40% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 69.53% |
| Reported EPS 12 Trailing Months | 0.00 |
| Reported EPS Past Year | 0.05 |
| Reported EPS Prior Year | -0.52 |
| Net Income Twelve Trailing Months | -278,000 |
| Net Income Past Year | -48,832,000 |
| Net Income Prior Year | -160,276,000 |
| Quarterly Revenue Growth YOY | 54.90% |
| 5-Year Revenue Growth | 23.35% |
| Operating Margin Twelve Trailing Months | 2.50% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 79,813,000 |
| Total Cash Past Year | 51,371,000 |
| Total Cash Prior Year | 31,167,000 |
| Net Cash Position Most Recent Quarter | -13,326,000 |
| Net Cash Position Past Year | -40,243,000 |
| Long Term Debt Past Year | 91,614,000 |
| Long Term Debt Prior Year | 91,614,000 |
| Total Debt Most Recent Quarter | 93,139,000 |
| Equity to Debt Ratio Past Year | 0.45 |
| Equity to Debt Ratio Most Recent Quarter | 0.51 |
| Total Stockholder Equity Past Year | 73,848,000 |
| Total Stockholder Equity Prior Year | 87,739,000 |
| Total Stockholder Equity Most Recent Quarter | 98,225,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 35,406,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 0.36 |
| Free Cash Flow Past Year | -46,907,000 |
| Free Cash Flow Prior Year | -128,511,000 |
Options |
|
| Put/Call Ratio | 2.44 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.07 |
| MACD Signal | 0.08 |
| 20-Day Bollinger Lower Band | 13.89 |
| 20-Day Bollinger Middle Band | 19.67 |
| 20-Day Bollinger Upper Band | 25.44 |
| Beta | 1.63 |
| RSI | 58.05 |
| 50-Day SMA | 13.67 |
| 150-Day SMA | 13.49 |
| 200-Day SMA | 11.64 |
System |
|
| Modified | 1/30/2026 5:59:20 PM EST |